Skip to content

Study · Non-randomized trial · n = 22 · 1995

6 results

Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.

Newhall-Perry K, Holloway L, Osburn L, Monroe SE, Heinrichs L, Henzl M, Marcus R

American journal of obstetrics and gynecology1 Sept 1995Cited by 6 (Europe PMC)

PMID7573251 (opens in a new tab)DOI10.1016/0002-9378(95)90348-8 (opens in a new tab)PepBankPUB-07573251
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women with endometriosis, L2-4 bone density fell 2.2% after 6 months of nafarelin and 3% 3 months later, returning toward baseline 6 months after treatment.

    In plain wordsIn women with endometriosis, spinal bone density fell during nafarelin treatment, then returned toward baseline.

    Peptide
    Nafarelin
    Outcome
    DecreaseL2-4 bone mineral density
    Study

    n = 22

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    L2-4 bone mineral density loss
    2.2%
    by 6 months
    L2-4 bone mineral density loss
    3%
    3 months after the 6-month assessment

    Source sentences

    Summary
    Subjects had a 2.2% loss in L2-4 bone mineral density by 6 months, increasing 3 months later to 3% and returning toward baseline by 6 months after treatment.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, radius bone mineral density did not change during nafarelin treatment.

    In plain wordsIn women with endometriosis, forearm bone density did not change during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeRadius bone mineral density
    Study

    n = 22

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Radius bone mineral density did not change in the treatment group.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, serum calcium rose during nafarelin treatment.

    In plain wordsIn women with endometriosis, blood calcium rose during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseSerum calcium
    Study

    n = 22

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum and urinary calcium levels rose during treatment.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.
  4. 04HumanNon-randomized trialSafety outcome

    In women with endometriosis, urinary calcium rose during nafarelin treatment.

    In plain wordsIn women with endometriosis, urine calcium rose during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseUrinary calcium
    Study

    n = 22

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum and urinary calcium levels rose during treatment.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.
  5. 05HumanNon-randomized trialSafety outcome

    In women with endometriosis, hydroxyproline excretion increased during nafarelin treatment and remained elevated 6 months afterward.

    In plain wordsIn women with endometriosis, hydroxyproline excretion rose during nafarelin treatment and remained high 6 months afterward.

    Peptide
    Nafarelin
    Outcome
    IncreaseHydroxyproline excretion
    Study

    n = 22

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Hydroxyproline excretion increased and remained elevated 6 months after treatment.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.
  6. 06HumanNon-randomized trialSafety outcome

    In women with endometriosis, serum osteocalcin rose with nafarelin, remained elevated 3 months after therapy, and normalized by 6 months.

    In plain wordsIn women with endometriosis, osteocalcin rose with nafarelin and returned to normal by 6 months after treatment.

    Peptide
    Nafarelin
    Outcome
    MixedSerum osteocalcin
    Study

    n = 22

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    A rise in serum osteocalcin persisted 3 months after therapy but normalized by 6 months.
    1 context sentence
    Summary · context
    We monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.